1. Home
  2. VYGR vs SABS Comparison

VYGR vs SABS Comparison

Compare VYGR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.89

Market Cap

222.4M

Sector

Health Care

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$4.34

Market Cap

187.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
SABS
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
222.4M
187.6M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
VYGR
SABS
Price
$3.89
$4.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$17.00
$9.80
AVG Volume (30 Days)
667.5K
461.1K
Earning Date
03-10-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,316,000.00
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
$71.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.65
$1.00
52 Week High
$5.78
$6.60

Technical Indicators

Market Signals
Indicator
VYGR
SABS
Relative Strength Index (RSI) 45.43 69.13
Support Level $3.86 $3.93
Resistance Level $4.11 $4.65
Average True Range (ATR) 0.25 0.26
MACD 0.01 0.04
Stochastic Oscillator 47.79 77.82

Price Performance

Historical Comparison
VYGR
SABS

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: